GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of securities laws, specifically related to misleading statements about the company's revenue outlook and the launch of its drug Rytelo [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Geron securities between June 7, 2024, and February 25, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Geron - The complaint alleges that Geron made false and misleading statements regarding its projected revenue and growth potential [4]. - The company reportedly provided an overly optimistic outlook on the launch and growth of Rytelo, failing to disclose that there was insufficient patient awareness to meet the claimed unmet need for the drug [4]. - As a result of these misleading statements, investors suffered damages when the truth about Geron's situation became known [4].